Survivors of childhood cancer face challenges from bone mineral density (BMD) deficits due to treatment exposures and other ...

The system is based on novel technology that promises to simplify treatment and delivery and increase the number of patients ...

London: GSK plc has announced that the US Food and Drug Administration (USFDA) has granted Breakthrough Therapy Designation for GSK5764227 (GSK'227), its B7-H3-targeted antibody-drug conjugate (ADC) ...

As it stands, just 3% of the U.S. population donates blood each year – despite 65% of the population being eligible to do so.

The FDA has granted BTD to GSK’22, a B7-H3-targeted antibody-drug conjugate, for the treatment of adult patients with ...

Myelosuppression, or bone marrow suppression, is defined as a decrease in the ability of the bone marrow to produce blood cells. This may result in a lack of red blood cells (anemia), white blood ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Bone cancer is characterized by uncontrolled growth of cells of the bone. Primary bone cancer (that arises directly in the bone), is relatively rare. Different types of bone tissue give rise to ...

GSK has gained US FDA breakthrough therapy designation for GSK'227 to treat adults with relapsed or refractory osteosarcoma.

We want to take a moment to recognize two extraordinary leaders within our wonderful school community. When we grow up, we ...

Learn about Acute Lymphoblastic Leukemia ALL including its symptoms treatment options and survival rates Expert share ...